Next generation therapies change the landscape in melanoma

Por Flaherty, Keith T.
Publicado em 2011

When are signal transduction targeted therapies acting as immunotherapy?

Por Flaherty, Keith T
Publicado no Cancer Biol Ther (2015)

BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance

Por Sullivan, Ryan J., Flaherty, Keith T.
Publicado em 2011

Targeting the RAS pathway in melanoma

Por Ji, Zhenyu, Flaherty, Keith T., Tsao, Hensin
Publicado em 2011

Mutation-driven drug development in melanoma

Por Flaherty, Keith T., Hodi, F. Stephen, Bastian, Boris C.
Publicado em 2010

Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer

Por Wargo, Jennifer A., Cooper, Zachary A., Flaherty, Keith T.
Publicado no Cancer Discov (2014)

Feeling energetic? New strategies to prevent metabolic reprogramming in melanoma

Por Verduzco, Daniel, Flaherty, Keith T., Smalley, Keiran S.M.
Publicado no Exp Dermatol (2015)

YAP in MAPK pathway targeted therapy resistance

Por Flaherty, Keith T, Wargo, Jennifer A, Bivona, Trever G
Publicado no Cell Cycle (2015)

Prognostic significance of cutaneous adverse events associated with pembrolizumab therapy

Por Lo, Jennifer A., Fisher, David E., Flaherty, Keith T.
Publicado no JAMA Oncol (2015)

The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: Where we have been, are, and will be

Por Sullivan, Ryan J., LoRusso, Patricia M., Flaherty, Keith T.
Publicado em 2013

The Conundrum of Genetic “Drivers” in Benign Conditions

Por Kato, Shumei, Lippman, Scott M., Flaherty, Keith T., Kurzrock, Razelle
Publicado no J Natl Cancer Inst (2016)

Melanoma: New Insights and New Therapies

Por Nikolaou, Vasiliki A., Stratigos, Alexander J., Flaherty, Keith T., Tsao, Hensin
Publicado em 2012

Precision medicine for cancer with next-generation functional diagnostics

Por Friedman, Adam A., Letai, Anthony, Fisher, David E., Flaherty, Keith T.
Publicado no Nat Rev Cancer (2015)

Overexpression of Mcl-1 confers resistance to BRAF(V600E) inhibitors alone and in combination with MEK1/2 inhibitors in melanoma

Por Fofaria, Neel M., Frederick, Dennie T., Sullivan, Ryan J., Flaherty, Keith T., Srivastava, Sanjay K.
Publicado no Oncotarget (2015)

BRAF inhibition generates a host/tumor niche that mediates therapeutic escape

Por Fedorenko, Inna V., Wargo, Jennifer A., Flaherty, Keith T., Messina, Jane L., Smalley, Keiran S.M.
Publicado no J Invest Dermatol (2015)

A Melanoma Molecular Disease Model

Por Vidwans, Smruti J., Flaherty, Keith T., Fisher, David E., Tenenbaum, Jay M., Travers, Michael D., Shrager, Jeff
Publicado em 2011

The Future of Preclinical Mouse Models in Melanoma Treatment Is Now

Por Merlino, Glenn, Flaherty, Keith, Pesantes, Nicolas Acquavella, Aplin, Andrew, Holmen, Sheri, Van Dyke, Terry, Herlyn, Meenhard
Publicado em 2013

BMET-04 LEPTOMENINGEAL CARCINOMATOSIS IN MELANOMA

Por Aquilanti, Elisa, Gill, Corey, Santagata, Sandro, Lawrence, Donald, Flaherty, Keith, Cahill, Daniel, Sullivan, Ryan, Brastianos, Priscilla
Publicado no Neuro Oncol (2015)

New challenges in endpoints for drug development in advanced melanoma

Por Ribas, Antoni, Hersey, Peter, Middleton, Mark R., Gogas, Helen, Flaherty, Keith T., Sondak, Vernon K., Kirkwood, John M.
Publicado em 2011

Pathways and therapeutic targets in melanoma

Por Shtivelman, Emma, Davies, Michael A., Hwu, Patrick, Yang, James, Lotem, Michal, Oren, Moshe, Flaherty, Keith T., Fisher, David E.
Publicado em 2014